164 related articles for article (PubMed ID: 32552897)
1. Thoracic perfusion of recombinant mutant human tumor necrosis factor (rmhTNF) can be considered as a good adjunct in the treatment of malignant pleural effusion caused by lung cancer.
Fu T; Lin Y; Zeng Q; Yao W; Han L
BMC Pulm Med; 2020 Jun; 20(1):175. PubMed ID: 32552897
[TBL] [Abstract][Full Text] [Related]
2. Thoracic perfusion of recombinant human endostatin (Endostar) combined with chemotherapeutic agents versus chemotherapeutic agents alone for treating malignant pleural effusions: a systematic evaluation and meta-analysis.
Biaoxue R; Xiguang C; Hua L; Wenlong G; Shuanying Y
BMC Cancer; 2016 Nov; 16(1):888. PubMed ID: 27842514
[TBL] [Abstract][Full Text] [Related]
3. Evaluation of efficacy and safety for recombinant human adenovirus-p53 in the control of the malignant pleural effusions via thoracic perfusion.
Biaoxue R; Hui P; Wenlong G; Shuanying Y
Sci Rep; 2016 Dec; 6():39355. PubMed ID: 27976709
[TBL] [Abstract][Full Text] [Related]
4. Evaluation of efficacy and safety for Brucea javanica oil emulsion in the control of the malignant pleural effusions via thoracic perfusion.
Fuhong D; Xiang G; Haiying L; Jiangye W; Xueming G; Wenxiao C
BMC Cancer; 2018 Apr; 18(1):411. PubMed ID: 29649989
[TBL] [Abstract][Full Text] [Related]
5. [A Meta-Analysis of Efficacy and Adverse Effects of Lobaplatin and Cisplatin in the Treatment of Malignant Pleural Effusion].
Min S; Zheng Q; Zhang B; Yan D; Wang R; Qu Z; Li L; Liu J; Zhou Q
Zhongguo Fei Ai Za Zhi; 2019 Feb; 22(2):90-98. PubMed ID: 30827325
[TBL] [Abstract][Full Text] [Related]
6. Effect of thoracic hyperthermic perfusion with recombinant human endostatin plus nedaplatin in treating pleural effusion in patients with advanced non-small cell lung cancer.
Chen L; Zhu X; Li D; Cai X
J BUON; 2020; 25(6):2643-2649. PubMed ID: 33455108
[TBL] [Abstract][Full Text] [Related]
7. Thoracic perfusion of lobaplatin combined with endostar for treating malignant pleural effusions: A meta-analysis and systematic review.
Wang CQ; Liu FY; Wang W
Medicine (Baltimore); 2022 Oct; 101(40):e30749. PubMed ID: 36221355
[TBL] [Abstract][Full Text] [Related]
8. Phase II multicenter, randomized, double-blind study of recombinant mutated human tumor necrosis factor-α in combination with chemotherapies in cancer patients.
Li M; Xu T; Zhang Z; Xue X; Zhang C; Qin X; Li W; Hao Q; Zhang W; Zhang Y
Cancer Sci; 2012 Feb; 103(2):288-95. PubMed ID: 22085427
[TBL] [Abstract][Full Text] [Related]
9. Recombinant mutated human TNF in combination with chemotherapy for stage IIIB/IV non-small cell lung cancer: a randomized, phase III study.
Ma X; Song Y; Zhang K; Shang L; Gao Y; Zhang W; Xue X; Jia H; Geng J; Zhou W; Dang Y; Li E; Ti X; Fan F; Zhang Y; Li M
Sci Rep; 2015 Apr; 4():9918. PubMed ID: 25897826
[TBL] [Abstract][Full Text] [Related]
10. Pharmacokinetic evaluation of intrapleural perfusion with hyperthermic chemotherapy using cisplatin in patients with malignant pleural effusion.
Sakaguchi H; Ishida H; Nitanda H; Yamazaki N; Kaneko K; Kobayashi K
Lung Cancer; 2017 Feb; 104():70-74. PubMed ID: 28213004
[TBL] [Abstract][Full Text] [Related]
11. Efficacy and safety of endostar combined with cisplatin in treatment of non-small cell lung cancer with malignant pleural effusion: A meta-analysis.
Hu Y; Zhou Z; Luo M
Medicine (Baltimore); 2022 Dec; 101(52):e32207. PubMed ID: 36595983
[TBL] [Abstract][Full Text] [Related]
12. rmhTNF-α combined with cisplatin inhibits proliferation of A549 cell line in vitro.
Xia LM; Zhou YY
Chin Med Sci J; 2014 Sep; 29(3):185-7. PubMed ID: 25264888
[TBL] [Abstract][Full Text] [Related]
13. Bevacizumab plus chemotherapy in nonsquamous non-small cell lung cancer patients with malignant pleural effusion uncontrolled by tube drainage or pleurodesis: A phase II study North East Japan Study group trial NEJ013B.
Noro R; Kobayashi K; Usuki J; Yomota M; Nishitsuji M; Shimokawa T; Ando M; Hino M; Hagiwara K; Miyanaga A; Seike M; Kubota K; Gemma A;
Thorac Cancer; 2020 Jul; 11(7):1876-1884. PubMed ID: 32421226
[TBL] [Abstract][Full Text] [Related]
14. [Clinical research on recombinant human Ad-p53 injection combined with cisplatin in treatment of malignant pleural effusion induced by lung cancer].
Zhao WZ; Wang JK; Li W; Zhang XL
Ai Zheng; 2009 Dec; 28(12):1324-7. PubMed ID: 19958629
[TBL] [Abstract][Full Text] [Related]
15. Evaluation of Efficacy and Safety for Lentinan in the Control of the Malignant Pleural Effusions via Intrapleural Injection.
Congcong Q; Hengting Z; Shuhui L; Fang Y; Shan W
Am J Med Sci; 2019 Dec; 358(6):400-411. PubMed ID: 31813467
[TBL] [Abstract][Full Text] [Related]
16. Thoracic injection of low-dose interleukin-2 as an adjuvant therapy improves the control of the malignant pleural effusions: a systematic review and meta-analysis base on Chinese patients.
Han L; Jiang Q; Yao W; Fu T; Zeng Q
BMC Cancer; 2018 Jul; 18(1):725. PubMed ID: 29980186
[TBL] [Abstract][Full Text] [Related]
17. [Therapeutical effects of pleural injecting recombinant human endostain to
malignant pleural effusion nude mice model].
Zhou M; Li M; Yang H; Hu C
Zhongguo Fei Ai Za Zhi; 2015 May; 18(5):266-71. PubMed ID: 25975296
[TBL] [Abstract][Full Text] [Related]
18. Clinical efficacy of bevacizumab combined with cisplatin in the treatment of malignant pleural effusion and ascites caused by lung cancer: a randomized trial.
Zhou Z; Li H; Hu D; Xie L
Ann Palliat Med; 2021 Oct; 10(10):10575-10583. PubMed ID: 34763504
[TBL] [Abstract][Full Text] [Related]
19. Intrapleural combination therapy with bevacizumab and cisplatin for non-small cell lung cancer‑mediated malignant pleural effusion.
Du N; Li X; Li F; Zhao H; Fan Z; Ma J; Fu Y; Kang H
Oncol Rep; 2013 Jun; 29(6):2332-40. PubMed ID: 23525453
[TBL] [Abstract][Full Text] [Related]
20. Outcomes of bevacizumab combined with chemotherapy in lung adenocarcinoma-induced malignant pleural effusion.
Tao H; Meng Q; Li M; Shi L; Tang J; Liu Z
Thorac Cancer; 2018 Feb; 9(2):298-304. PubMed ID: 29297985
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
